Communiqués Novelion Therapeutics Inc.

Actions

NVLNF

CA67001K2020

Temps Différé OTC Markets			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-4,49%	-0,54%

29/03/22	Novelion Therapeutics Inc. annonce la distribution finale en espèces, payable le ou vers le 31 mars 2022	CI
07/05/19	Novelion Therapeutics Inc. fournit les prévisions de résultats pour l'année 2019.	CI

Communiqués

30/09/20	Novelion Therapeutics Provides Update on Liquidation Process	GL
08/07/20	Novelion Therapeutics Ceases to be a Reporting Issuer in Canada	GL
15/06/20	Novelion Therapeutics : Provides Update on Liquidation and Claims Process	AQ
12/06/20	Novelion Therapeutics Provides Update on Liquidation and Claims Process	GL
17/01/20	Novelion Therapeutics Confirms Commencement of Voluntary Liquidation	GL
10/01/20	NOVELION THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/01/20	Novelion Therapeutics Announces January 16, 2020 Effective Date for Commencement of Voluntary Liquidation	GL
06/01/20	Novelion Therapeutics : Provides Updates on Voluntary Liquidation and Other Matters	AQ
03/01/20	NOVELION THERAPEUTICS INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/12/19	Novelion Therapeutics Provides Update on Effective Date of Liquidation	GL
05/11/19	Novelion Therapeutics Announces Results of 2019 Annual General Meeting of Shareholders	GL
08/10/19	Novelion Therapeutics Announces Nasdaq Delisting	GL
04/10/19	Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters	GL
11/09/19	Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders	GL
21/08/19	Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq	GL
12/08/19	Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019	GL
17/07/19	Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition	GL
05/07/19	Novelion Therapeutics Receives Delisting Notifications	GL
24/06/19	Novelion Therapeutics Responds to Whitefort Capital Petition	GL
21/05/19	Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion	GL
07/05/19	Novelion Therapeutics Reports First Quarter 2019 Financial Results	GL
14/03/19	Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results	GL
09/11/18	Novelion Therapeutics Reports Third Quarter 2018 Financial Results	GL
08/11/18	Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update	GL
24/09/18	Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day	GL